The company anticipates the next opening of a branch in Spain, with a broad portfolio of quality products.
In Milan, on May 12, NTC Pharma organised Leader7 Investigators’ Meeting with 90 ophthalmologists representing 57 Italian centers, OPIS Group team and NTC people involved in this clinical research project, one of the widest multicentre clinical studies conducted in Europe in Ophthalmology. NTC is strongly committed in the fight against antibiotic resistance as demonstrated by this study and other initiatives that are building the path of NTC to the Next Level.
NTC is engaged in developing novel therapeutic solutions to satisfy unmet medical needs. On top of large clinical efforts to support its novelties with therapeutic evidences, NTC seeks new innovative solutions to improve a patient friendly and educational approach.